Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Current Deferred Revenue (2016 - 2025)

Iradimed (IRMD) has disclosed Current Deferred Revenue for 13 consecutive years, with $3.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Current Deferred Revenue rose 23.6% to $3.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was $3.2 million, a 23.6% increase, with the full-year FY2024 number at $2.3 million, down 12.09% from a year prior.
  • Current Deferred Revenue was $3.2 million for Q3 2025 at Iradimed, down from $3.3 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $3.4 million in Q4 2022 to a low of $1.6 million in Q3 2022.
  • A 5-year average of $2.5 million and a median of $2.5 million in 2024 define the central range for Current Deferred Revenue.
  • Peak YoY movement for Current Deferred Revenue: surged 58.74% in 2021, then plummeted 35.05% in 2022.
  • Iradimed's Current Deferred Revenue stood at $2.6 million in 2021, then soared by 32.12% to $3.4 million in 2022, then fell by 23.8% to $2.6 million in 2023, then fell by 12.09% to $2.3 million in 2024, then surged by 39.76% to $3.2 million in 2025.
  • Per Business Quant, the three most recent readings for IRMD's Current Deferred Revenue are $3.2 million (Q3 2025), $3.3 million (Q2 2025), and $2.6 million (Q1 2025).